Cesar A. Santa‐Maria
YOU?
Author Swipe
View article: Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data
Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data Open
Purpose: Despite current standard-of-care endocrine therapy, distant recurrence remains a concern for patients with hormone receptor–positive (HR+)/HER2− early breast cancer (EBC). Understanding individual recurrence risk would aid in clin…
View article: BIOM-56. A FEASIBILITY STUDY UTILIZING SEQUENTIAL CEREBROSPINAL FLUID (CSF) - BASED LIQUID BIOPSY AND AMIDE PROTON TRANSFER (APT) MRI TO DIFFERENTIATE DISEASE PROGRESSION FROM RADIATION NECROSIS IN PATIENTS WITH BRAIN METASTASIS FROM SOLID TUMORS
BIOM-56. A FEASIBILITY STUDY UTILIZING SEQUENTIAL CEREBROSPINAL FLUID (CSF) - BASED LIQUID BIOPSY AND AMIDE PROTON TRANSFER (APT) MRI TO DIFFERENTIATE DISEASE PROGRESSION FROM RADIATION NECROSIS IN PATIENTS WITH BRAIN METASTASIS FROM SOLID TUMORS Open
BACKGROUND Brain metastases affect 30–40% of patients with solid tumors, and as systemic therapies improve survival, intracranial recurrences are more common. Radiation therapy is standard of care treatment but can frequently lead to radia…
View article: MMAP-07 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH ALPELISIB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
MMAP-07 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH ALPELISIB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS Open
BACKGROUND Alpelisib is FDA-approved for patients with HR-positive, HER-2 negative, PIK3CA-mutated metastatic breast cancer with progression on/after receiving endocrine therapy. We investigated the CNS progression patterns of patients on …
View article: MMAP-08 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH SACITUZUMAB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
MMAP-08 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH SACITUZUMAB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS Open
BACKGROUND Sacituzumab is FDA approved for unresectable locally advanced or metastatic triple-negative or HR-positive/HER2-negative breast cancer in the metastatic setting. Sacituzumab’s ability to prevent or control CNS disease is not yet…
View article: OGCT-02 A TRANSLATIONAL OBSERVATIONAL BIOREPOSITORY AND MANAGEMENT STUDY IN PATIENTS WITH BREAST CANCER LEPTOMENINGEAL METASTASIS: THE BIOLEPT STUDY
OGCT-02 A TRANSLATIONAL OBSERVATIONAL BIOREPOSITORY AND MANAGEMENT STUDY IN PATIENTS WITH BREAST CANCER LEPTOMENINGEAL METASTASIS: THE BIOLEPT STUDY Open
BACKGROUND Leptomeningeal disease (LMD) is a devastating complication of breast cancer (with high rates of morbidity and mortality) and breast cancer accounts for almost 30% of LMD cases. Despite the advances in the treatment of breast can…
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers Open
Purpose The standard-of-care neoadjuvant treatment for early-stage or locally advanced triple negative breast cancer (TNBC) is the KEYNOTE-522 regimen that combines pembrolizumab and chemotherapy. Although this approach has superior respon…
Bi-level graph learning unveils prognosis-relevant tumor microenvironment patterns in breast multiplexed digital pathology Open
The tumor microenvironment (TME) is widely recognized for its central role in driving cancer progression and influencing prognostic outcomes. Increasing efforts have been dedicated to characterizing it, including its analysis with modern d…
View article: NCMP-16. CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH CDK4/6 INHIBITORS: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
NCMP-16. CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH CDK4/6 INHIBITORS: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS Open
BACKGROUND CDK4/6 inhibitors combined with hormonal therapy or as monotherapy (abemaciclib) play an important role in the management of hormone receptor positive, HER-2 negative breast cancer (BC). To date, these drugs were shown to improv…
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade Open
Patients with metastatic triple-negative breast cancer (TNBC) show variable responses to PD-1 inhibition. Efficient patient selection by predictive biomarkers would be desirable but is hindered by the limited performance of existing biomar…
View article: Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 fami…
View article: Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer Open
Importance: Agents targeting programmed death ligand 1 (PD-L1) have demonstrated efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are now the standard of care in patients with PD-L1-positive metastatic d…
View article: Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion Open
Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.
View article: TRSC-02 RESPONSE TO PARP INHIBITORS IN PATIENTS WITH BREAST CANCER METASTATIC TO THE CENTRAL NERVOUS SYSTEM
TRSC-02 RESPONSE TO PARP INHIBITORS IN PATIENTS WITH BREAST CANCER METASTATIC TO THE CENTRAL NERVOUS SYSTEM Open
BACKGROUND Central nervous system (CNS) metastasis from breast cancer can be challenging to treat due to the limited blood brain barrier penetration of many systemic therapies. The goal of our study is to describe the clinical benefit of P…
View article: Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022 Open
We observed intracranial activity for neratinib plus T-DM1, including those with prior T-DM1 exposure, suggesting synergistic effects with neratinib. Our data provide additional evidence for neratinib-based combinations in patients with HE…
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade Open
Patients with metastatic triple-negative breast cancer (TNBC) show variable responses to PD-1 inhibition. Efficient patient selection by predictive biomarkers would be desirable, but is hindered by the limited performance of existing bioma…
Bi-level Graph Learning Unveils Prognosis-Relevant Tumor Microenvironment Patterns in Breast Multiplexed Digital Pathology Open
The tumor microenvironment is widely recognized for its central role in driving cancer progression and influencing prognostic outcomes. There have been increasing efforts dedicated to characterizing this complex and heterogeneous environme…
View article: Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Nanostring gene expression data related to Figure 5 and Figure S5 with related metatdata tables.
View article: FIGURE 6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
B7-H4 expression does not correlate with resistance to chemotherapy + immunotherapy in human breast tumors. Patients were from the I-SPY2 clinical trial (paclitaxel control and pembrolizumab arms) or the TBCRC 043 clinical trial (carboplat…
View article: Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 6. EMT6 tumors do not respond to single-agent chemotherapy. (A) EMT6 parental or B7-H4+ tumors treated with vehicle (isotype control), anti-PD-L1, paclitaxel chemotherapy, or anti-PD-L1 + paclitaxel (n=15/group parental…
View article: Table S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplementary Table 2. DE genes between isotype treated and anti-PD-L1 treated EMT6-B7-H4+ tumors.
View article: Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Nanostring gene expression data related to Figure 5 and Figure S5 with related metatdata tables.
View article: FIGURE 2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
B7-H4 (VTCN1) is highly correlated with epithelial gene markers in mouse and human cells unlike other checkpoint ligands. A, In human breast cancer cell lines (CCLE), B7-H4 is the only checkpoint ligand positively correlated with epithelia…
View article: Table S3 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S3 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplementary Table 3. DE genes between isotype treated EMT6 and EMT6-B7-H4+ tumors, early timepoint, 7 days post isotype treatment.
View article: FIGURE 1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
B7-H4 is associated with immune cold tumors and correlated with worse outcomes. A, Representative TNBC samples (residual disease, post-NAC) categorized on the basis of CD8 T-cell infiltration and localization into ID, MR, SR, and FI. B, B7…
View article: Figure S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 2. B7-H4 expression is not affected by type I or II interferon or TGF-β treatment in vitro. MMTV-neu epithelial cells that have high levels of endogenous B7-H4 were treated for 72 hours with IFNα or IFNγ at 100ng/mL. B7…
View article: FIGURE 5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Anti-PD-L1 did not induce a proinflammatory immune response in B7-H4+ tumors. CD45+ cells were sorted from EMT6 tumors ± B7-H4 and subjected to NanoString gene expression analysis using the Mouse Pan-Cancer Immune Panel. A, Differentially …
View article: Figure S4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 4. B7-H4 expression did not change quantity of infiltrating tumor immune cells in vivo regardless of anti-PD-L1 treatment. Untreated and anti-PD-L1 treated EMT6 tumors ± B7-H4 were dissociated to single cell suspension …
View article: Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 6. EMT6 tumors do not respond to single-agent chemotherapy. (A) EMT6 parental or B7-H4+ tumors treated with vehicle (isotype control), anti-PD-L1, paclitaxel chemotherapy, or anti-PD-L1 + paclitaxel (n=15/group parental…